Consistent with these data from the pivotal trials, preliminary evidence from studies of early adoption of oral semaglutide in the US also suggests real-world improvements in glycemic control, with a mean HbA 1c reduction of 0.9% observed across patients [85, 86]
doi: 10.1210/endo.139.4.5921 48 NauckMABartelsEOrskovCEbertRCreutzfeldtW
R., Hannibal, L., Warren, M
In the context of mitohormesis, growing evidence indicates that an authentic lifestyle aimed at balancing (1) cognitive stimulation, exercise, and psychosocial engagement sessions (challenging, not excessive, stressor phases) with (2) dedicated sleep and deep rest practices (complete, not excessive, recovery phases) offers promise as a preventative and therapeutic strategy for neurodegenerative disorders
The key difference is clinical oversight
It is the latest step in a concerted push by the pharmaceutical industry to develop an oral treatment to rival the results of the GLP-1 injectable medications, which have surged in popularity